42 results about "Pulmonary Macrophages" patented technology

Disclosed are compositions and methods relating to growth of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) using non-simian cells. In a particular example, porcine alveolar macrophage cells are described as having a capability of supporting infectivity and reproduction by PRRSV. Cells and cell lines of the invention are disclosed in connection with applications relating to PRRS disease, including vaccine technologies.

The present invention is directed to methods and compositions for improving pulmonary surfactant catabolism. More specifically, the specification describes methods and compositions for making and using a lysosomal phospholipase A2 in methods for the diagnosis, and treatment of disorders of phospholipid catabolism such as pulmonary alveolar proteinosis.

The invention belongs to the field of medical science, and provides a method which is used for preparing a silicosis cell model from a molecular level, is simple, and can accurately represent pulmonary fibrosis in vivo. The method comprises the specific steps: adopting silicious dust to stimulate alveolar macrophages cultured to a stationary period, after 24 h, collecting a supernatant, filtering, and removing bacteria; and adding the silicious dust and the alveolar macrophage supernatant into lung adenocarcinoma cells A549 cultured to a stationary period, jointly incubating lung epithelial cells with the two substances, and completing establishment of the silicosis cell model.

The invention discloses a probiotic composition and its preparation and application, comprising VSL#3, Lactobacillus rhamnosus M9 and Lactobacillus plantarum P‑8; the VSL#3, rhamnosus Saccharobacillus M9 and Lactobacillus plantarum P‑8 were mixed in an equal ratio of 1:1:1. The application of the probiotic composition in the preparation of medicines for treating or preventing pneumonia, especially pneumonia caused by respiratory syncytial virus infection, especially infant bronchopneumonia caused by respiratory syncytial virus infection. The probiotic composition of the present invention can alleviate the change of the inflammatory pathological structure of the lung tissue caused by RSV infection, and can inhibit the virus infection process of RSV infection; it can activate TLR3 and RIG-1 signaling pathways in alveolar macrophages to promote IFN-1 The production of β can inhibit the expression of lung inflammatory factors; it can regulate the lung flora and intestinal flora to relieve RSV virus infection.